Skip to main content
Blue Key CBD
Sign in

Provider Center

Cannabinoid resources for clinicians.

Free, unbranded resources for physicians, nurses, pharmacists, and allied health professionals. No sign-up required.

Clinician in a light blue coat reviewing a printed patient handout with a patient in a bright clinic room

  • Clinical summaries

    One-page overviews of key indications with references to primary literature.

  • Dosing frameworks

    Start-low-go-slow templates and titration schedules for common conditions.

  • Patient handouts

    Printable education pieces in accessible reading levels, English and Spanish.

  • Interaction quick-checks

    CYP450 interaction reference for common medications.

A conservative titration framework

Full- and broad-spectrum CBD have wide therapeutic windows, so tolerability rather than a ceiling dose is usually the limiting factor. This schedule is a starting point for otherwise healthy adults; adjust for hepatic impairment, polypharmacy, and frailty.

Suggested CBD titration schedule for adults by phase, dose, and monitoring note
PhaseSuggested doseMonitoring
Days 1–310–15 mg CBD once dailyEvening dosing for sleep or anxiety concerns; morning for daytime pain. Document baseline symptom scores before the first dose.
Days 4–1010–15 mg twice dailyHold here if the patient reports meaningful benefit. Reassess sedation, GI upset, and appetite change.
Days 11–21Increase 5–10 mg per dose weeklyMost adults settle between 25 and 60 mg per day. Step up only when tolerability is clean at the current dose.
Beyond week 3Reassess or taperIf there is no response at roughly 60 mg/day for two weeks, taper off rather than escalating indefinitely.

Drug interaction quick-check

Common medication classes, the cytochrome pathway involved, and the suggested clinical action
MedicationPathwaySuggested action
Warfarin and other VKAsCYP2C9 inhibitionCheck INR weekly for the first month after starting or changing the CBD dose.
Clobazam, valproateCYP2C19 / active metabolite accumulationExpect added sedation; consider a proactive benzodiazepine dose reduction and monitor LFTs with valproate.
Tacrolimus, cyclosporineCYP3A4 inhibitionObtain trough levels before and after initiation, and coordinate with the transplant team.
SSRIs, SNRIs, TCAsCYP2C19 / CYP2D6Usually tolerated; watch for additive sedation at higher CBD doses.
Opioids and benzodiazepinesAdditive CNS depressionCounsel on drowsiness and driving. No documented respiratory-depression synergy, but start low.
Pharmacist in a white coat reviewing a medication list on a clipboard at a bright pharmacy counter

CBD inhibits CYP3A4, CYP2C9, and CYP2C19 in a dose-dependent way. Interactions matter most above roughly 25 mg per day and with narrow-therapeutic-index medications.

How to read a Certificate of Analysis

Close-up of a blank printed lab report page beside black reading glasses and a pen on a bright desk
  • The batch number on the COA matches the batch printed on the product label.
  • The testing laboratory is ISO/IEC 17025 accredited and independent of the manufacturer.
  • The cannabinoid panel reports total CBD and total THC in mg per unit, not only percentages.
  • The report date falls within 12 months of the product's manufacture date.
  • Pesticide, heavy metal, residual solvent, and microbial panels are all present and passing.

Evidence summaries by indication

Each collection summarizes what the literature supports, what remains uncertain, and links out to the primary studies.

Counseling points for the visit

  1. Set expectations. CBD is not an analgesic in the NSAID sense. Most patients describe reduced reactivity to a symptom rather than its elimination.
  2. Give a time horizon. Ask for a two-week trial at a steady dose with a simple daily log before judging effect.
  3. Name the side effects. Drowsiness, dry mouth, loose stools, and appetite change are the common ones, and they are usually dose-related.
  4. Address THC directly. Hemp products may contain up to 0.3% THC by dry weight, which can produce a positive workplace drug screen.
  5. Document it. Record the product, batch, mg per dose, and indication in the chart the same way you would any supplement.
Neat stack of blank printed patient handouts and a notebook on a bright clinic desk beside a small plant

Provider FAQ

Do you provide product samples to clinics?
We provide unbranded education packets at no cost. Product samples are handled separately through our wholesale team and are not part of the provider resource packet.
Are these materials branded?
Patient handouts are unbranded by default so they can be used in any clinical setting. A co-branded version is available on request.
Can I get the COA for a specific batch?
Yes. Email the batch number printed on the product label and we will send the full third-party panel, usually the same business day.
Do you offer continuing education credit?
Not currently. Our summaries are reference material and cite primary literature so you can review the sources directly.
BlueKey COMP provider dashboard showing patient outcomes, pain reduction, sleep improvement, anxiety improvement, adherence, and clinical success metrics

Request provider access

Clinics and practices can request bulk patient handouts and educational packets at no cost. Tell us a bit about your practice and we'll send your resource packet within two business days. Prefer email? Reach us at providers@bluekeycbd.com.

All fields marked required must be completed. Errors will be summarized after submission.

Resources of interest

Select all that apply.

We reply within two business days. No cost, no obligation.

These materials are educational and are not medical advice, a treatment protocol, or a substitute for your clinical judgment. These statements have not been evaluated by the FDA. Blue Key CBD products are not intended to diagnose, treat, cure, or prevent any disease.

🔑 Find My Blue Key